Loading
Latest filing published 30 Apr 2026 for 명문제약, €12k. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
우석민, listed as chief executive, appears in our data through filings on 명문제약 shares, published by DART (FSS). In total, 29 filings cover trades dated from 31 August 2021 to 28 April 2026.
Every open-market trade on record is a purchase: 25 purchases worth €12k, and no sale. The amount is not disclosed for 24 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 1 purchase and no sales.
The 25 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 30 April 2026, reports an open-market purchase of €12k in 명문제약. The median gap between a trade and its publication by DART (FSS) is 3 days. Until a filing is published, the market cannot know about the trade. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 29 declarations